EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro evolution of durlobactam resistance in NDM-producing Escherichia coli due to a single mutation in mrdA encoding penicillin-binding protein 2

Christi L McElheny iD, Erika L Butcher, Akito Kawai iD, Robert M Q Shanks iD, Ryan K Shields iD, Yohei Doi iD

Antimicrobial Agents and Chemotherapy · 05.11.2025 · 69 (11)

DOI: 10.1128/aac.01014-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.11.2025. Verfasst von Christi L McElheny und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Escherichia coli, Penicillin-Binding Proteins, beta-Lactamases, Anti-Bacterial Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NEI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Durlobactam, a diazabicyclooctane β-lactamase inhibitor, exhibits direct antibacterial activity by binding to penicillin-binding protein 2 (PBP2). We generated a mutant strain of New Delhi metallo-β-lactamase-producing Escherichia coli with a durlobactam minimum inhibitory concentration of 2 µg/mL, representing a 16-fold increase from baseline, by exposing it to increasing concentrations of durlobactam. Resistance was attributed to a point mutation in the mrdA gene, resulting in a V522I substitution in PBP2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Escherichia coliPenicillin-Binding Proteinsbeta-LactamasesAnti-Bacterial AgentsEscherichia coli ProteinsAzabicyclo Compoundsbeta-Lactamase InhibitorsMicrobial Sensitivity TestsMutation

Stichwörter der Autor:innen

durlobactampenicillin-binding proteinβ-lactam inhibitor

Substanzen

Penicillin-Binding Proteinsbeta-LactamasesAnti-Bacterial AgentsEscherichia coli ProteinsAzabicyclo CompoundsMrdA protein, E colibeta-Lactamase Inhibitors

Autor:innen und Institutionen

  • Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
  • UPMC Eye Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Center for Innovative Antimicrobial Therapy, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Christi L McElheny, Akito Kawai, Robert M Q Shanks, Ryan K Shields, Yohei Doi

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • NEI NIH HHS
  • Research to Prevent Blindness
  • Eye and Ear Foundation of Pittsburgh
  • National Institutes of Health

Zitieren

APA

McElheny, C. L., Butcher, E. L., Kawai, A., Shanks, R. M. Q., Shields, R. K., & Doi, Y. (2025). In vitro evolution of durlobactam resistance in NDM-producing Escherichia coli due to a single mutation in mrdA encoding penicillin-binding protein 2. Antimicrobial Agents and Chemotherapy, 69(11). https://doi.org/10.1128/aac.01014-25

Vancouver

McElheny CL, Butcher EL, Kawai A, Shanks RMQ, Shields RK, Doi Y. In vitro evolution of durlobactam resistance in NDM-producing Escherichia coli due to a single mutation in mrdA encoding penicillin-binding protein 2. Antimicrobial Agents and Chemotherapy. 2025;69(11). doi:10.1128/aac.01014-25

BibTeX
@article{McElheny2025,
  author = {McElheny, Christi L and Butcher, Erika L and Kawai, Akito and Shanks, Robert M Q and Shields, Ryan K and Doi, Yohei},
  title = {In vitro evolution of durlobactam resistance in NDM-producing Escherichia coli due to a single mutation in mrdA encoding penicillin-binding protein 2},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {11},
  doi = {10.1128/aac.01014-25}
}
Kostenlos starten →